Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 143% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 30.0% — good return on equity
Novartis AG (NVS) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NYSE , with a market capitalisation of $293.9 billion . Key value metrics: P/E ratio 21.0, P/B ratio 6.31, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Novartis AG — Fundamental Analysis Summary
Novartis AG (NVS) is currently trading 143% above its Graham Number of $63.38, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 21.0x.
On financial health, NVS shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 30.0% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.62.
StockPik's composite Value Score for NVS is 59/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
NVS shows earnings growing at 17%.